Tvardi Therapeutics Inc banner

Intrinsic Value

The intrinsic value of Tvardi Therapeutics Inc (69C) under the Base Case is 5.24 EUR per share. Compared with the current market price of 0.8 EUR, the stock appears Undervalued by 85% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

69C Intrinsic Value
€5.24
Undervaluation 85%
Intrinsic Value
Price €0.8
Alert me when 69C is below its intrinsic value
Today €4.19 · Already reached, the price is 80.9% below it

69C is cheaper than usual. It was this cheap or cheaper on just 2% of days in the past 5 years.

Alternatives to 69C

Fundamental Analysis

What Tvardi Therapeutics Does

Pharmaceuticals Health Care

Cara Therapeutics is a biopharmaceutical company that develops prescription medicines for severe itch and pain. Its work has centered on drug candidates that act on the body’s opioid receptors, especially the kappa opioid receptor, which it studies as a way to relieve symptoms without relying on traditional painkillers. In simple terms, it is a drug developer, not a drug distributor or clinic operator.

Headquarters
United States of America US
Employees
12
IPO date
Jan 31, 2014
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue 69C Research

Decided on Tvardi Therapeutics? Get an email when 69C reaches the price you’d buy at. Free with an account.

Other Tvardi Therapeutics listings

What is the Intrinsic Value of one 69C stock?

The intrinsic value for Tvardi Therapeutics Inc (69C) under the Base Case is 5.24 EUR.

Is 69C stock undervalued or overvalued?

Compared with the current market price of 0.8 EUR, the stock appears Undervalued by 85% .

How reliable are our estimates? See how past valuations played out
Back to Top